![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
An Evaluation of Neutropenia in the Pivotal Studies of Boceprevir Plus Peginterferon alfa-2b/Ribavirin
|
|
|
Reported by Jules Levin
AASLD Nov 5-8 2011 SF
K. R. Reddy1, F. Nunes2, L. Balart3, R. Sjogren4, L. D. Pedicone5, M. Burroughs5, C. Brass5, J. Albrecht5, and M. Sulkowski6
1University of Pennsylvania, Philadelphia, PA, USA; 2P.H.G.I. Associates, Ltd., Philadelphia, PA, USA; 3Tulane University Health Sciences Center, New Orleans, LA, USA; 4Kaiser Permanente, Falls Church, VA, USA; 5Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA; 6Johns Hopkins University School of Medicine, Baltimore, MD, USA
![AASLD1.gif](../images/112211/112211-2/AASLD1.gif)
![AASLD2.gif](../images/112211/112211-2/AASLD2.gif)
![AASLD3.gif](../images/112211/112211-2/AASLD3.gif)
![AASLD4.gif](../images/112211/112211-2/AASLD4.gif)
![AASLD5.gif](../images/112211/112211-2/AASLD5.gif)
![AASLD6.gif](../images/112211/112211-2/AASLD6.gif)
![AASLD7.gif](../images/112211/112211-2/AASLD7.gif)
![AASLD8.gif](../images/112211/112211-2/AASLD8.gif)
![AASLD9.gif](../images/112211/112211-2/AASLD9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|